Clinical Trials Using Trastuzumab

Clinical trials are research studies that involve people. The clinical trials on this list are studying Trastuzumab. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 51-63 of 63

  • Sargramostim and Trastuzumab in Treating Younger Patients with Recurrent Ependymoma

    This phase I clinical trial studies the side effects and best dose of trastuzumab when given together with sargramostim in treating younger patients with ependymoma that have returned after a period of improvement. Monoclonal antibodies, such as trastuzumab, may block tumor growth in different ways by targeting certain cells. Colony-stimulating factors, such as sargramostim, may increase the production of blood cells and may help the immune system recover from the side effects of chemotherapy. Giving trastuzumab with sargramostim may work better in treating younger patients with recurrent ependymoma.
    Location: Children's Hospital Colorado, Aurora, Colorado

  • Carboplatin and Paclitaxel with Pertuzumab and Trastuzumab or Bevacizumab in Treating Patients with Breast Cancer

    This phase II trial studies the side effects and how well carboplatin and paclitaxel given in combination with pertuzumab and trastuzumab or bevacizumab work in treating patients with breast cancer. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as pertuzumab and bevacizumab, may interfere with the ability of tumor cells to grow and spread. Trastuzumab is a form of targeted therapy because it works by attaching itself to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors. When trastuzumab attaches to HER2 receptors, the signals that tell the cells to grow are blocked and the cancer cell may be marked for destruction by the body's immune system. Giving carboplatin and paclitaxel together with pertuzumab and trastuzumab or bevacizumab may kill more tumor cells.
    Location: UC Irvine Health / Chao Family Comprehensive Cancer Center, Orange, California

  • Personalized Antibodies in Treating Patients with Metastatic Stomach or Gastroesophageal Junction Cancer

    This pilot phase II trial studies personalized antibodies in treating patients with stomach or gastroesophageal junction cancer that has spread to other parts of the body. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies may block tumor growth in different ways by targeting certain cells. Testing tumor tissue for gene mutations and protein expression patterns and using drugs that target the specific profile of the tumor, may work better than standard chemotherapy in treating patients with stomach or gastroesophageal junction cancer.
    Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois

  • Chemotherapy before Surgery and Tissue Sample Collection in Patients with Stage IIA-IIIC Breast Cancer

    This randomized pilot clinical trial studies chemotherapy before surgery and tissue sample collection in patients with stage IIA-IIIC breast cancer. Drugs used in chemotherapy, such as doxorubicin hydrochloride, cyclophosphamide, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as trastuzumab, may interfere with the ability of tumor cells o grow and spread. Giving doxorubicin hydrochloride, cyclophosphamide, paclitaxel and trastuzumab may kill more tumor cells. Collecting and storing samples of tissue from patients with breast cancer to study in the laboratory may help doctors learn more about how well patients will respond to treatment.
    Location: Montefiore Medical Center-Weiler Hospital, Bronx, New York

  • Trastuzumab in Treating Leptomeningeal Metastases in Patients with HER2-Positive Cancer

    This phase I / II trial studies the side effects and best dose of trastuzumab and to see how well it works in treating cancer that has spread to the thin layers of tissue that cover and protect the brain and spinal cord (meninges) in patients with certain nervous system tumors or patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Monoclonal antibodies, such as trastuzumab, may interfere with the ability of tumor cells to grow and spread.
    Location: 2 locations

  • Cyclophosphamide and Vaccine Therapy with or without Trastuzumab in Treating Patients with Stage IV Breast Cancer

    This trial studies cyclophosphamide and vaccine therapy with or without trastuzumab in treating patients with stage IV breast cancer. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Vaccines made from gene-modified tumor cells may help the body build an effective immune response to kill tumor cells. Immunotherapy with trastuzumab, may induce changes in body’s immune system and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether cyclophosphamide and vaccine therapy is more effective when given together with or without trastuzumab in treating patients with breast cancer.
    Location: Johns Hopkins University / Sidney Kimmel Cancer Center, Baltimore, Maryland

  • A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies

    This is a global, multicenter, open-label safety extension study. Participants receiving single-agent trastuzumab emtansine or trastuzumab emtansine administered in combination with other anti-cancer therapies in a Genentech / Roche-sponsored parent study who are active and receiving benefit at the closure of parent study are eligible for continued treatment in this study.
    Location: Translational Oncology Research International, Los Angeles, California

  • MCLA-128 With Trastuzumab / Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer

    A Phase 2, open-label, multicenter international study will be performed to evaluate the efficacy of MCLA-128-based combinations. Three combination treatments will be evaluated, two in Cohort 1 and one in Cohort 2. MCLA-128 is given in combinations in two metastatic breast cancer (MBC) populations, HER2-positive / amplified (Cohort 1) and Estrogen Receptor-positive / low HER2 expression (Cohort2). Two combinations treatments will be evaluated in Cohort 1, the doublet and triplet. Initially MCLA-128 is given in combination with trastuzumab in the doublet. After the safety of the doublet has been assessed in 4-6 patients, MCLA-128 is given in combination with trastuzumab and vinorelbine in the triplet, in parallel to the efficacy expansion of the doublet. The doublet and triplet combinations are both evaluated in two steps with an initial safety run-in followed by a cohort efficacy expansion. In total up to 40 patients evaluable for efficacy are included in both the doublet and triplet. In Cohort 2 MCLA-128 is administered in combination with the same previous endocrine therapy on which progressive disease is radiologically documented. A total of up to 40 patients evaluable for efficacy are included in the Cohort 2.
    Location: See Clinical Trials.gov

  • Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy before Surgery for the Treatment of Patients with Breast Cancer

    This phase II trial studies the immunologic response and side effects of using the WOKVAC vaccine in combination with chemotherapy and HER2-targeted monoclonal antibody therapy before surgery in treating patients with breast cancer. Vaccines like WOKVAC are made from tumor-associated antigens which may help the body build an effective immune response to kill tumor cells. Chemotherapy drugs, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Trastuzumab and pertuzumab are forms of targeted therapy because they work by attaching themselves to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When trastuzumab and pertuzumab attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Giving the WOKVAC vaccine at the same time (concurrently) with paclitaxel, trastuzumab, and pertuzumab before surgery may kill more tumor cells.
    Location: Fred Hutch / University of Washington Cancer Consortium, Seattle, Washington

  • Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation

    The purpose of this two parts multicenter, randomized, double-blind, placebo-controlled, Phase III study is to evaluate the efficacy and safety of alpelisib compared to alpelisib matching-placebo in combination with trastuzumab and pertuzumab as maintenance treatment of patients with HER2-positive advanced breast cancer whose tumor harbors a PIK3CA mutation following induction therapy with a taxane in combination with trastuzumab and pertuzumab. Part 1 is the open-label, safety run-in part of the study, designed to confirm the recommended phase 3 dose (RP3D) dose of alpelisib in combination with trastuzumab and pertuzumab. Following Part 1, Part 2 will be initiated, which is the randomized, Phase III part of the study.
    Location: 3 locations

  • Fluorouracil, Oxaliplatin, Liposomal Irinotecan with or without Trastuzumab for the First Line Treatment of Advanced Esophageal or Gastric Adenocarcinoma

    This phase II trial studies how well fluorouracil, oxaliplatin, and liposomal irinotecan work alone or with trastuzumab in treating patients with esophageal or gastric adenocarcinoma that has spread to other places in the body (advanced). Drugs used in chemotherapy, such as fluorouracil, oxaliplatin, and liposomal irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as trastuzumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving fluorouracil, oxaliplatin, liposomal irinotecan, and trastuzumab may work as a first line treatment for esophageal or gastric adenocarcinoma.
    Location: University of Wisconsin Hospital and Clinics, Madison, Wisconsin

  • Paclitaxel and Carboplatin before Surgery in Treating Nigerian Women with Stage IIA-IIIC Breast Cancer

    This phase II trial studies how well paclitaxel works with carboplatin before surgery in treating Nigerian women with stage IIA-IIIC breast cancer before surgery. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
    Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois

  • Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

    This pilot phase I trial studies the side effects of direct tumor microinjection and fludeoxyglucose F-18 positron emission tomography (FDG-PET) in testing drug sensitivity in patients with non-Hodgkin lymphoma, Hodgkin lymphoma, or stage IV breast cancer that has returned after a period of improvement or does not respond to treatment. Injecting tiny amounts of anti-cancer drugs directly into tumors on the skin or in lymph nodes and diagnostic procedures, such as FDG-PET, may help to show which drugs work better in treating patients with non-Hodgkin lymphoma, Hodgkin lymphoma, or breast cancer.
    Location: Mayo Clinic, Rochester, Minnesota